Herantis Pharma Oyj - Asset Resilience Ratio

Latest as of June 2025: 89.18%

Herantis Pharma Oyj (HRTIS) has an Asset Resilience Ratio of 89.18% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€4.56 Million

≈ $5.33 Million USD Cash + Short-term Investments

Total Assets

€5.11 Million

≈ $5.98 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2024)

This chart shows how Herantis Pharma Oyj's Asset Resilience Ratio has changed over time. Check HRTIS PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Herantis Pharma Oyj's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HRTIS stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€446.00K	8.72%
Short-term Investments	€4.11 Million	80.46%
Total Liquid Assets	€4.56 Million	89.18%

Asset Resilience Insights

Very High Liquidity: Herantis Pharma Oyj maintains exceptional liquid asset reserves at 89.18% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Herantis Pharma Oyj Industry Peers by Asset Resilience Ratio

Compare Herantis Pharma Oyj's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Samsung Biologics Co Ltd KO:207940	Biotechnology	5.66%
Abivax SA PA:ABVX	Biotechnology	2.34%
Merus BV NASDAQ:MRUS	Biotechnology	29.69%
Suzhou Zelgen Biopharmaceuticals Co Ltd SHG:688266	Biotechnology	0.54%
Beijing Hotgen Biotech Co Ltd SHG:688068	Biotechnology	20.87%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Starlake Bioscience Co Inc Zhaoqing Guangdong SHG:600866	Biotechnology	0.29%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%

Annual Asset Resilience Ratio for Herantis Pharma Oyj (2012–2024)

The table below shows the annual Asset Resilience Ratio data for Herantis Pharma Oyj.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	83.02%	€2.13 Million ≈ $2.50 Million	€2.57 Million ≈ $3.01 Million	-13.16pp
2023-12-31	96.18%	€6.49 Million ≈ $7.59 Million	€6.75 Million ≈ $7.89 Million	+0.06pp
2022-12-31	96.13%	€5.99 Million ≈ $7.00 Million	€6.23 Million ≈ $7.29 Million	+14.98pp
2020-12-31	81.15%	€13.32 Million ≈ $15.58 Million	€16.42 Million ≈ $19.20 Million	+72.25pp
2019-12-31	8.90%	€985.24K ≈ $1.15 Million	€11.07 Million ≈ $12.94 Million	-11.62pp
2018-12-31	20.52%	€1.47 Million ≈ $1.71 Million	€7.15 Million ≈ $8.36 Million	-25.38pp
2017-12-31	45.90%	€5.31 Million ≈ $6.21 Million	€11.57 Million ≈ $13.53 Million	+25.84pp
2016-12-31	20.06%	€2.05 Million ≈ $2.39 Million	€10.21 Million ≈ $11.93 Million	-15.43pp
2015-12-31	35.49%	€5.00 Million ≈ $5.85 Million	€14.09 Million ≈ $16.47 Million	+4.98pp
2014-12-31	30.51%	€9.00 Million ≈ $10.52 Million	€29.49 Million ≈ $34.48 Million	--
2012-12-31	0.00%	€0.00 ≈ $0.00	€2.21 Million ≈ $2.59 Million	--

pp = percentage points

About Herantis Pharma Oyj

HE:HRTIS Finland Biotechnology

Market Cap

$52.37 Million

€44.79 Million EUR

Market Cap Rank

#21697 Global

#108 in Finland

Share Price

€1.69

Change (1 day)

-1.05%

52-Week Range

€1.58 - €2.78

All Time High

€10.10